Cantor Fitzgerald lowered the firm’s price target on SI-Bone to $25 from $30 and keeps an Overweight rating on the shares following the “record” Q3 revenue and raised guidance. The firm believes adoption of SI-Bone’s iFuse procedure will continue to accelerate in CY23 as the company benefits from a more-diversified portfolio, higher physician fees, improved sales-force productivity, positive five-year data, and broader insurance coverage, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SIBN:
- SI-Bone reports Q3 EPS (25c), consensus (34c)
- SI-BONE, Inc. Reports Record Financial Results for the Third Quarter 2023 and Raises Annual Guidance
- Is SIBN a Buy, Before Earnings?
- SI-BONE To Present at Jefferies London Healthcare Conference on November 15, 2023
- SI-Bone price target lowered to $24 from $33 at BofA
